Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.

Literature DB >> 19815834

Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.

Paul T Telfer, Fiona Warburton, Soteroula Christou, Michael Hadjigavriel, Maria Sitarou, Anita Kolnagou, Michael Angastiniotis.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19815834 PMCID： PMC2791948 DOI： 10.3324/haematol.2009.009118

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

10 in total

1. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004.

Authors: Paul Telfer; Pietro G Coen; Soteroula Christou; Michael Hadjigavriel; Anita Kolnakou; Evangelia Pangalou; Nicos Pavlides; Michael Psiloines; Krikor Simamonian; Georghios Skordos; Maria Sitarou; Michael Angastiniotis
Journal: Haematologica Date: 2006-09 Impact factor: 9.941

2. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.

Authors: Caterina Borgna-Pignatti; Maria Domenica Cappellini; Piero De Stefano; Giovanni Carlo Del Vecchio; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Maria Antonietta Romeo; Huaqing Zhao; Avital Cnaan
Journal: Blood Date: 2005-12-22 Impact factor: 22.113

3. Combined therapy with deferiprone and desferrioxamine.

Authors: B Wonke; C Wright; A V Hoffbrand
Journal: Br J Haematol Date: 1998-11 Impact factor: 6.998

4. Combined therapy with deferiprone and desferrioxamine in thalassemia major.

Authors: Raffaella Origa; Patrizio Bina; Annalisa Agus; Gabriella Crobu; Elisabetta Defraia; Carlo Dessì; GiovanBattista Leoni; Pier Paolo Muroni; Renzo Galanello
Journal: Haematologica Date: 2005-10 Impact factor: 9.941

5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.

Authors: S Daar; A V Pathare
Journal: Ann Hematol Date: 2006-02-01 Impact factor: 3.673

6. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.

Authors: B Modell; M Khan; M Darlison
Journal: Lancet Date: 2000-06-10 Impact factor: 79.321

7. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial.

Authors: Antonis Kattamis; Vassilios Ladis; Helen Berdousi; Nikolaos L Kelekis; Efthymia Alexopoulou; Ioannis Papasotiriou; Kalliopi Drakaki; Irini Kaloumenou; Aggeliki Galani; Christos Kattamis
Journal: Blood Cells Mol Dis Date: 2006-01-04 Impact factor: 3.039

8. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

Authors: Caterina Borgna-Pignatti; Simone Rugolotto; Piero De Stefano; Huaqing Zhao; Maria Domenica Cappellini; Giovanni Carlo Del Vecchio; Maria Antonietta Romeo; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Avital Cnaan
Journal: Haematologica Date: 2004-10 Impact factor: 9.941

9. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.

Authors: Yesim Aydinok; Zulal Ulger; Deniz Nart; Aysen Terzi; Nurten Cetiner; Gareth Ellis; Arthur Zimmermann; Chantal Manz
Journal: Haematologica Date: 2007-12 Impact factor: 9.941

10. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.

Authors: Bernadette Modell; Maren Khan; Matthew Darlison; Mark A Westwood; David Ingram; Dudley J Pennell
Journal: J Cardiovasc Magn Reson Date: 2008-09-25 Impact factor: 5.364

10 in total

30 in total

1. The life of patients with thalassemia major.

Authors: Caterina Borgna-Pignatti
Journal: Haematologica Date: 2010-03 Impact factor: 9.941

2. Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.

Authors: Nicoletta Masera; Luisa Tavecchia; Daniela Valentina Longoni; Oscar Maglia; Andrea Biondi; Giuseppe Masera
Journal: Blood Transfus Date: 2011-07-18 Impact factor: 3.443

Review 3. Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in β-Thalassemia Major Patients.

Authors: Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Gerardo Nigro
Journal: Ann Noninvasive Electrocardiol Date: 2016-06-20 Impact factor: 1.468

4. New developments and controversies in iron metabolism and iron chelation therapy.

Authors: Christina N Kontoghiorghe; George J Kontoghiorghes
Journal: World J Methodol Date: 2016-03-26

5. Assessment of Heart and Liver Iron Overload in Thalassemia Major Patients Using T2* Magnetic Resonance Imaging.

Authors: Hamid Farhangi; Zahra Badiei; Hasan Mottaghi Moghaddam; Mohammad Reza Keramati
Journal: Indian J Hematol Blood Transfus Date: 2016-06-15 Impact factor: 0.900

Review 6. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors: Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal: World J Methodol Date: 2014-09-26

7. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study.

Authors: Maria Marsella; Caterina Borgna-Pignatti; Antonella Meloni; Valeria Caldarelli; Maria Chiara Dell'Amico; Anna Spasiano; Lorella Pitrolo; Eliana Cracolici; Gianluca Valeri; Vincenzo Positano; Massimo Lombardi; Alessia Pepe
Journal: Haematologica Date: 2011-01-12 Impact factor: 9.941